General American Investors Co. Inc. Boosts Stake in Paratek Pharmaceuticals Inc (PRTK)

General American Investors Co. Inc. lifted its holdings in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 6.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 464,985 shares of the specialty pharmaceutical company’s stock after purchasing an additional 28,621 shares during the period. General American Investors Co. Inc.’s holdings in Paratek Pharmaceuticals were worth $2,385,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Hsbc Holdings PLC purchased a new position in shares of Paratek Pharmaceuticals in the fourth quarter worth about $59,000. Annex Advisory Services LLC lifted its stake in shares of Paratek Pharmaceuticals by 15.3% in the fourth quarter. Annex Advisory Services LLC now owns 15,100 shares of the specialty pharmaceutical company’s stock worth $77,000 after buying an additional 2,000 shares in the last quarter. Stifel Financial Corp purchased a new position in shares of Paratek Pharmaceuticals in the fourth quarter worth about $90,000. Telemetry Investments L.L.C. purchased a new position in Paratek Pharmaceuticals during the fourth quarter worth about $113,000. Finally, Bank of America Corp DE raised its stake in Paratek Pharmaceuticals by 43.1% during the fourth quarter. Bank of America Corp DE now owns 23,504 shares of the specialty pharmaceutical company’s stock worth $120,000 after purchasing an additional 7,074 shares during the period. 74.30% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PRTK stock opened at $5.77 on Monday. The company has a current ratio of 14.41, a quick ratio of 14.41 and a debt-to-equity ratio of 4.81. Paratek Pharmaceuticals Inc has a 12 month low of $4.50 and a 12 month high of $14.15. The stock has a market cap of $187.04 million, a price-to-earnings ratio of -1.62 and a beta of 1.55.

A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Canaccord Genuity set a $25.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, March 18th. LADENBURG THALM/SH SH set a $18.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, February 28th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Thursday, February 28th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $23.25.

TRADEMARK VIOLATION NOTICE: This news story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2019/03/25/general-american-investors-co-inc-boosts-stake-in-paratek-pharmaceuticals-inc-prtk.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

See Also: What is the Gross Domestic Product (GDP)?

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.